Jordan Warnsholz, PA
Physician Assistant · Wellston, MINPI 1649692732
Payments from drug & device makers
Across 534 payments — averaging $15.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AstraZeneca$898
- GSK$843
- AbbVie$713
- Astellas Pharma US Inc$545
- Novo Nordisk$333
- plus $3K from 32 others
What the payments were for
- Food & beverage$7,87397%
- Education$2673%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 127 | $1,614 |
| AstraZeneca | 40 | $898 |
| GSK | 80 | $843 |
| AbbVie(2 entities) | 51 | $713 |
| Astellas Pharma US Inc | 17 | $545 |
| Novo Nordisk | 19 | $333 |
| Axsome Therapeutics, Inc. | 18 | $318 |
| Bayer | 17 | $279 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $257 |
| Corium, LLC | 22 | $246 |
| Antares Pharma, Inc. | 11 | $201 |
| Sunovion Pharmaceuticals Inc. | 22 | $189 |
| Verona Pharma, Inc. | 16 | $161 |
| Lilly USA, LLC | 7 | $139 |
| Otsuka America Pharmaceutical, Inc. | 7 | $132 |
| Halozyme Inc | 6 | $109 |
| Boehringer Ingelheim | 5 | $109 |
| Teva Pharmaceuticals USA, Inc. | 6 | $108 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Exact Sciences | 4 | $90 |
| Mylan Specialty L.p. | 4 | $79 |
| Esperion Therapeutics, Inc. | 4 | $74 |
| Johnson & Johnson | 4 | $68 |
| Eisai Inc. | 3 | $61 |
| Pfizer | 3 | $53 |
| Lundbeck LLC | 3 | $53 |
| Amgen | 2 | $49 |
| Biohaven Pharmaceuticals, Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Viatris Specialty LLC | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
| Alkermes, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $15 |
| Novartis | 1 | $14 |
| Kyowa Kirin, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,140 in reported general payments places this provider in the 95th percentile of 5,453 physician assistant providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 200 | $186,509 |
| EliquisApixaban | 101 | $109,962 |
| TrulicityDulaglutide | 74 | $76,108 |
| JardianceEmpagliflozin | 61 | $64,849 |
| MounjaroTirzepatide | 41 | $49,891 |
| CaplytaLumateperone Tosylate | 23 | $48,721 |
| FarxigaDapagliflozin Propanediol | 30 | $42,590 |
| MyrbetriqMirabegron | 40 | $38,093 |
| OzempicSemaglutide | 26 | $35,679 |
| RexultiBrexpiprazole | 17 | $34,658 |
| InvokanaCanagliflozin | 18 | $26,414 |
| KerendiaFinerenone | 11 | $25,102 |
| JanuviaSitagliptin Phosphate | 22 | $24,797 |
| LinzessLinaclotide | 26 | $24,725 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $21,323 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta | $843 | $202,450222 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $139 | $126,000115 claims |
| PfizerEliquis | $53 | $109,962101 claims |
| Boehringer IngelheimJardiance | $109 | $64,84961 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $898 | $63,91362 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,614 | $48,72123 claims |
| AbbVieLinzess, Creon | $713 | $45,98143 claims |
| Johnson & JohnsonInvokana, Xarelto | $68 | $39,60738 claims |
| Astellas Pharma US IncMyrbetriq | $545 | $38,09340 claims |
| Novo NordiskOzempic | $333 | $35,67926 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $132 | $34,65817 claims |
| BayerKerendia | $279 | $25,10211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,453 physician assistant providers in Michigan.
Other physician assistant in Wellston
- Sarang PatelRoyal Oak$660K
- Beth SweneyAda$617K
- Zainab JishiCanton$596K
- Taylor HennrickAdrian$430K
- Erin van DykeGrand Rapids$346K
- Ashley AldridgeAnn Arbor$298K
- Derek SusallaRochester Hills$242K
- Gabrielle DamoreRoyal Oak$200K
- Melissa MickelsonKalamazoo$168K
- Patrick CooneyNew Baltimore$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.